TARS vs ZBH
Tarsus Pharmaceuticals, Inc. vs Zimmer Biomet — AI-powered side-by-side comparison
TARS
Tarsus Pharmaceuticals, Inc.
63
Buy
VS
| Metric | TARS | ZBH |
|---|
| AI Score |
63
|
69
|
| Price |
$69.50
|
$97.22
|
| P/E Ratio |
-63.72×
|
23.54×
|
| ROE |
-19.3%
|
5.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
90.6%
|
69.9%
|
| Debt / Equity |
0.26×
|
0.59×
|
| Dividend Yield |
0.0%
|
1.0%
|
| RSI (14) |
80.7
|
63.1
|
| Beta |
0.512
|
0.462
|
| Expected Upside |
—
|
+3.7%
|
AI Committee View
Current Innellis committee reasoning for TARS versus ZBH.
ZBH leads by 6 points.
ZBH scores 69/100 (Buy) versus TARS at 63/100 (Buy).
TARS Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Revenue growing 105.2% YoY -- genuine top-line momentum — Growth
- MACD histogram positive -- bullish momentum — Technical
- Low leverage (debt-to-equity 0.21) -- balance sheet can absorb a shock — Risk
Bear Case
- Price-to-book of 10.1x prices in significant intangible value — Value
- ROE of only -13.5% -- cheap may mean cheap for a reason — Value
- RSI at 81 is in overbought territory — Technical
ZBH Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical